These newly developed PAR2 antagonists may be applied alone or in combination with TGF-β signaling inhibitors that are already in clinical use for anti-cancer therapy of advanced PDAC and HCC tumors [64]. This evidence concerns the gene F2RL1 and hepatocellular carcinoma.